Cargando…

Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

Detalles Bibliográficos
Autores principales:	Gandhi, Rajesh T., Zheng, Lu, Bosch, Ronald J., Chan, Ellen S., Margolis, David M., Read, Sarah, Kallungal, Beatrice, Palmer, Sarah, Medvik, Kathy, Lederman, Michael M., Alatrakchi, Nadia, Jacobson, Jeffrey M., Wiegand, Ann, Kearney, Mary, Coffin, John M., Mellors, John W., Eron, Joseph J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934995/ http://dx.doi.org/10.1371/annotation/fcb608e3-54c2-4cf8-b1d9-34e86196013f

Ejemplares similares

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
por: Gandhi, Rajesh T., et al.
Publicado: (2010)

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
por: Archin, Nancie M., et al.
Publicado: (2010)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy
por: Tosiano, Melissa A., et al.
Publicado: (2022)

Modelling HIV-1 2-LTR dynamics following raltegravir intensification
por: Luo, Rutao, et al.
Publicado: (2013)

Intensification of antiretroviral treatment with raltegravir for pregnant women living with HIV at high risk of vertical transmission
por: Puthanakit, Thanyawee, et al.
Publicado: (2018)

Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia
por: Garrido, C, et al.
Publicado: (2010)

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine
por: Funderburg, Nicholas T., et al.
Publicado: (2013)

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs
por: Puertas, Maria C, et al.
Publicado: (2018)

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
por: Jacobs, Jana L., et al.
Publicado: (2019)

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy
por: Li, Jonathan Z., et al.
Publicado: (2014)

ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
por: Maldarelli, Frank, et al.
Publicado: (2007)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Automated Multireplicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy
por: Jacobs, Jana L., et al.
Publicado: (2020)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
por: Chirch, Lisa M, et al.
Publicado: (2010)

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults
por: Kearney, Mary F., et al.
Publicado: (2018)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Impact of Chemotherapy for HIV-1 Related Lymphoma on Residual Viremia and Cellular HIV-1 DNA in Patients on Suppressive Antiretroviral Therapy
por: Cillo, Anthony R., et al.
Publicado: (2014)

A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil
por: Kaur, Rupinderjeet, et al.
Publicado: (2006)

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
por: Archin, NM, et al.
Publicado: (2012)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

Predictors of Viremia in Postpartum Women on Antiretroviral Therapy
por: Hoffman, Risa M., et al.
Publicado: (2020)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
por: Gandhi, Rajesh, et al.
Publicado: (2020)

555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
por: Lackey, Philip, et al.
Publicado: (2018)

A12 Modeling residual HIV replication and the emergence of drug resistance on ART
por: Michael Bale, J, et al.
Publicado: (2019)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
por: Kityo, Cissy, et al.
Publicado: (2018)

Multiple Sources of Contamination in Samples from Patients Reported to Have XMRV Infection
por: Kearney, Mary F., et al.
Publicado: (2012)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Well-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy
por: Kearney, Mary F., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kg6qt5p50c0t5cog99qj06avdo